aliskiren vs eprosartan
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of aliskiren and eprosartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not co-administer aliskiren with eprosartan in patients with diabetes. Avoid use of aliskiren with eprosartan in patients with renal impairment (GFR < 60 mL/min).
Tekturna
Teveten
Tekturna is a medicine used to treat high blood pressure. It helps lower blood pressure, which can reduce the risk of strokes and heart attacks.
Eprosartan (Teveten) is a medicine that lowers high blood pressure. It can be used alone or with other blood pressure medicines.
Tekturna is used to treat high blood pressure in adults and children who weigh at least 110 pounds and are 6 years or older. Lowering your blood pressure helps prevent strokes and heart attacks. It is important to manage high blood pressure with a healthy lifestyle too.
Eprosartan is used to treat high blood pressure (hypertension). It can be used by itself or with other medicines to lower your blood pressure. Lowering blood pressure helps prevent strokes, heart attacks, and kidney problems.
Tekturna works by blocking a substance in your body called renin. Renin helps to control your blood pressure. By blocking renin, Tekturna helps to lower your blood pressure.
Eprosartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs). It works by blocking a substance in your body that tightens blood vessels. This helps blood vessels relax, which lowers blood pressure.
- • Diarrhea
- • Viral infection
- • Injury
- • Fatigue
- • Abdominal pain
- • Joint pain
- Asthenia 367
- Fall 356
- Nausea 336
- Dyspnoea 315
- Headache 301
No adverse event reports.
Tekturna can harm your unborn baby, even causing death. If you become pregnant, stop taking Tekturna right away and tell your doctor.
If you become pregnant, stop taking eprosartan right away. This medicine can cause serious harm or death to your unborn baby.
Tekturna can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, talk to your doctor about other blood pressure medicines. Breastfeeding is not recommended while taking Tekturna.
Eprosartan can harm your unborn baby, even causing death. Stop taking this medicine as soon as you know you are pregnant. It is not known if eprosartan passes into breast milk, so talk to your doctor about the best way to feed your baby if you are taking this medicine.
Also Compare, Nearby Drugs
Compare eprosartan with
How to Read This aliskiren vs eprosartan Comparison
aliskiren is classified in the Direct Renin Inhibitor drug class, while eprosartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aliskiren has 1,675 submissions while eprosartan has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to both drugs work on the same system to lower blood pressure, which can cause blood pressure to drop too low or harm the kidneys.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aliskiren or eprosartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.